| Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma (NCT07623681) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2026-06-10 |
| Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies (NCT07338604) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2025-12-12 |
| Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies (NCT07284927) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2025-12-03 |
| PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma (NCT07188610) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2025-09-25 |
| Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies (NCT07312630) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2025-09-25 |
| Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection. (NCT06982534) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2025-06-01 |
| Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases (NCT06970951) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2025-05-18 |
| Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases (NCT06871644) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2025-03-18 |
| Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases (NCT06417398) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2024-05-14 |
| Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases (NCT06361745) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2024-04-02 |
| UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma (NCT06279026) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2024-04-01 |
| UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. (NCT06092047) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2023-10-01 |
| TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (NCT05562024) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2022-12-30 |
| Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05722171) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2022-12-27 |
| UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (NCT05731219) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2022-09-26 |
| TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia (NCT05432401) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2022-06-09 |
| PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies (NCT05170568) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-12-01 |
| TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia (NCT05017883) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-07-01 |
| A Clinical Trial of TAA06 Injection in Advanced Solid Tumors (NCT05190185) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-06-01 |
| Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor (NCT04864821) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-05-14 |
| CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia (NCT04785833) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-03-04 |
| CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study (NCT04480788) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2020-11-24 |
| CAR-T for r/r Malignant Tumors in Children (NCT04691349) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2020-09-27 |
| CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors (NCT04702841) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2020-06-03 |
| γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse (NCT04439721) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2020-05-01 |
| TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia (NCT04692948) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-12-09 |
| CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors (NCT04691713) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-09-01 |
| CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia (NCT04004637) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-08-25 |
| CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma (NCT04237428) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-05-31 |
| Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma (NCT04186052) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-03-08 |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies (NCT03999697) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-12-01 |
| Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor (NCT04650724) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-10-11 |
| The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies (NCT04184414) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-01-09 |